|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
3
|
|
pubmed:dateCreated |
2009-3-5
|
|
pubmed:abstractText |
Imiquimod use in the treatment of basal cell carcinoma (BCC) has proven to be successful in a large percentage of cases, inducing tumor regression; however, the exact cellular mechanism has not been fully clarified.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Mar
|
|
pubmed:issn |
1365-4632
|
|
pubmed:author |
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
48
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
312-21
|
|
pubmed:meshHeading |
pubmed-meshheading:19261026-Administration, Cutaneous,
pubmed-meshheading:19261026-Adult,
pubmed-meshheading:19261026-Aged,
pubmed-meshheading:19261026-Aged, 80 and over,
pubmed-meshheading:19261026-Aminoquinolines,
pubmed-meshheading:19261026-Antigens, CD3,
pubmed-meshheading:19261026-Antigens, CD4,
pubmed-meshheading:19261026-Antineoplastic Agents,
pubmed-meshheading:19261026-Apoptosis,
pubmed-meshheading:19261026-Carcinoma, Basal Cell,
pubmed-meshheading:19261026-Female,
pubmed-meshheading:19261026-Humans,
pubmed-meshheading:19261026-Inflammation,
pubmed-meshheading:19261026-Male,
pubmed-meshheading:19261026-Middle Aged,
pubmed-meshheading:19261026-Ointments,
pubmed-meshheading:19261026-Skin Neoplasms,
pubmed-meshheading:19261026-T-Lymphocyte Subsets
|
|
pubmed:year |
2009
|
|
pubmed:articleTitle |
In vivo characterization of the inflammatory infiltrate and apoptotic status in imiquimod-treated basal cell carcinoma.
|
|
pubmed:affiliation |
Dipartimento di Scienze Dermatologiche, Università degli Studi di Firenze, Florence, Italy.
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Research Support, Non-U.S. Gov't
|
